| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ingrid Morales, Manuel Rodrigue. Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia. vol 60. issue 10. 2013-01-15. PMID:22715058. |
excitotoxicity induced by high levels of extracellular glutamate (glu) has been proposed as a cause of cell degeneration in basal ganglia disorders. |
2013-01-15 |
2023-08-12 |
rat |
| Ingrid Morales, Manuel Rodrigue. Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia. vol 60. issue 10. 2013-01-15. PMID:22715058. |
this massive and persistent self-induced glutamate accumulation in striatal astrocytes could be an additional factor for the glu-induced excitotoxicity, which has been implicated in the progression of different basal ganglia disorders. |
2013-01-15 |
2023-08-12 |
rat |
| Daniella Rylande. The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166409. |
furthermore, serotonin can influence dyskinesia by modulating glutamate or gaba signalling in the basal ganglia via receptors located on non-serotonergic neurons. |
2012-08-27 |
2023-08-12 |
Not clear |
| James W Bogenpohl, Stefanie L Ritter, Randy A Hall, Yoland Smit. Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. The Journal of comparative neurology. vol 520. issue 3. 2012-08-23. PMID:21858817. |
adenosine a2a receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. |
2012-08-23 |
2023-08-12 |
rat |
| Melissa L Perreault, Theresa Fan, Mohammed Alijaniaram, Brian F O'Dowd, Susan R Georg. Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. PloS one. vol 7. issue 3. 2012-08-20. PMID:22428025. |
the identification of a msn with dual inhibitory and excitatory intrinsic functions provides new insights into the neuroanatomy of the basal ganglia and demonstrates a novel source of glutamate in this circuit. |
2012-08-20 |
2023-08-12 |
Not clear |
| Iain S McGregor, Michael T Bowe. Breaking the loop: oxytocin as a potential treatment for drug addiction. Hormones and behavior. vol 61. issue 3. 2012-06-25. PMID:22198308. |
very recent preclinical studies have illustrated a remarkable ability of exogenously delivered oxytocin to inhibit stimulant and alcohol self-administration, to alter associated drug-induced changes in dopamine, glutamate and fos expression in cortical and basal ganglia sites, and to prevent stress and priming-induced relapse to drug seeking. |
2012-06-25 |
2023-08-12 |
Not clear |
| Véronique Sgambato-Faure, Maria Angela Cenc. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. vol 96. issue 1. 2012-05-07. PMID:22075179. |
accumulating evidence indicates that dyskinesias induced by stn-hfs and dopamine replacement therapy are linked to dysregulation of glutamate transmission in the basal ganglia. |
2012-05-07 |
2023-08-12 |
rat |
| Véronique Sgambato-Faure, Maria Angela Cenc. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. vol 96. issue 1. 2012-05-07. PMID:22075179. |
these findings lay the ground for therapeutic development initiatives targeting dysfunctional components of glutamate transmission in the basal ganglia. |
2012-05-07 |
2023-08-12 |
rat |
| Andrzej Dekundy, Andreas Gravius, Mirko Hechenberger, Małgorzata Pietraszek, Jens Nagel, Carsten Tober, Martine van der Elst, Flora Mela, Christopher G Parsons, Wojciech Danys. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21161716. |
subtype 5 metabotropic glutamate receptors (mglur5) are abundant in the basal ganglia, amygdala, septum, hippocampus, peripheral sensory neurones and dorsal horn of the spinal cord. |
2012-03-30 |
2023-08-12 |
rat |
| Shesharao M Wanjerkhede, Raju S Bap. Role of CAMKII in reinforcement learning: a computational model of glutamate and dopamine signaling pathways. Biological cybernetics. vol 104. issue 6. 2011-10-24. PMID:21701878. |
(in: houk et al (eds) models of information processing in the basal ganglia, (1995) proposed a cellular signaling pathway model to characterize the interaction between da and glutamate pathways that have a role in rl. |
2011-10-24 |
2023-08-12 |
Not clear |
| Andrew P Prescot, Allison E Locatelli, Perry F Renshaw, Deborah A Yurgelun-Tod. Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. NeuroImage. vol 57. issue 1. 2011-10-19. PMID:21349338. |
previous proton magnetic resonance spectroscopy studies have demonstrated reduced basal ganglia glutamate and dorsolateral prefrontal cortex n-acetyl aspartate levels in adult chronic marijuana users. |
2011-10-19 |
2023-08-12 |
human |
| Lucile Capuron, Andrew H Mille. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacology & therapeutics. vol 130. issue 2. 2011-07-22. PMID:21334376. |
pathways that appear to be especially important in immune system effects on the brain include the cytokine signaling molecules, p38 mitogen-activated protein kinase and nuclear factor kappa b; indoleamine 2,3 dioxygenase and its downstream metabolites, kynurenine, quinolinic acid and kynurenic acid; the neurotransmitters, serotonin, dopamine and glutamate; and neurocircuits involving the basal ganglia and anterior cingulate cortex. |
2011-07-22 |
2023-08-12 |
Not clear |
| M S Nandhu, Jes Paul, Korah P Kuruvilla, Anitha Malat, Chinthu Romeo, C S Paulos. Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation. Journal of biomedical science. vol 18. 2011-04-28. PMID:21235809. |
increased glutamatergic transmission in the basal ganglia is implicated in the pathophysiology of parkinson's disease and glutamate receptor mediated excitotoxicity has been suggested to be one of the possible causes of the neuronal degeneration. |
2011-04-28 |
2023-08-12 |
rat |
| Alberto Martire, Maria Teresa Tebano, Valentina Chiodi, Samira G Ferreira, Rodrigo A Cunha, Attila Köfalvi, Patrizia Popol. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. Journal of neurochemistry. vol 116. issue 2. 2011-01-20. PMID:21062287. |
in view of the key role of glutamate to trigger the recruitment of striatal circuits, this pre-synaptic interaction between cb(1) r and a(2a) r may be of relevance for the pathogenesis and the treatment of neuropsychiatric disorders affecting the basal ganglia. |
2011-01-20 |
2023-08-12 |
rat |
| Susan Dut. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. British journal of pharmacology. vol 161. issue 2. 2011-01-04. PMID:20735415. |
group iii metabotropic glutamate (mglu) receptors were first identified in the basal ganglia a decade ago. |
2011-01-04 |
2023-08-12 |
Not clear |
| Sergi Ferré, Carme Lluís, Zuzana Justinova, César Quiroz, Marco Orru, Gemma Navarro, Enric I Canela, Rafael Franco, Steven R Goldber. Adenosine-cannabinoid receptor interactions. Implications for striatal function. British journal of pharmacology. vol 160. issue 3. 2010-10-14. PMID:20590556. |
in this review we will focus on their common role as modulators of dopamine and glutamate neurotransmission in the striatum, the main input structure of the basal ganglia. |
2010-10-14 |
2023-08-12 |
Not clear |
| Véronique M André, Carlos Cepeda, Michael S Levin. Dopamine and glutamate in Huntington's disease: A balancing act. CNS neuroscience & therapeutics. vol 16. issue 3. 2010-09-22. PMID:20406248. |
significant evidence indicates that glutamate and dopamine neurotransmission is affected in hd, compromising the fine balance in which da modulates glutamate-induced excitation in the basal ganglia and cortex. |
2010-09-22 |
2023-08-12 |
Not clear |
| Javier Fernández-Ruiz, Mariluz Hernández, José A Ramo. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS neuroscience & therapeutics. vol 16. issue 3. 2010-09-22. PMID:20406253. |
through this direct mechanism or through indirect mechanisms involving gaba or glutamate neurons, cannabinoids may interact with da transmission in the cns and this has an important influence in various da-related neurobiological processes (e.g., control of movement, motivation/reward) and, particularly, on different pathologies affecting these processes like basal ganglia disorders, schizophrenia, and drug addiction. |
2010-09-22 |
2023-08-12 |
Not clear |
| Nicolas Vallee, Jean-Claude Rostain, Jean-Jacques Riss. A pressurized nitrogen counterbalance to cortical glutamatergic pathway stimulation. Neurochemical research. vol 35. issue 5. 2010-07-08. PMID:20111995. |
we sought to establish the hypothetical role of the glutamatergic corticostriatal pathway because of the glutamate deficiency which occurs in the basal ganglia in this hyperbaric syndrome. |
2010-07-08 |
2023-08-12 |
rat |
| A F Iakimovskiĭ, Iu A Red'ka, A L Iakubenk. [The blocade of glutamate metabotropic 5-th tipe receptors prevents the locomotor behavior changes produced by intrastriatal picrotoxin microinjections in rats]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. vol 60. issue 1. 2010-07-06. PMID:20352688. |
in principle, it might be possible to treat the human hyperkinetic basal ganglia dysfunction (huntington's horea), athetosis and similar disorders with glutamate metabotropic receptor antagonists. |
2010-07-06 |
2023-08-12 |
human |